TRF has led numerous clinical trials of rAAV gene therapy over the past 25 years, including the first-ever human trial, a rAAV2-CFTR trial in cystic fibrosis patients. More recent work has focused on genetic emphysema due to alpha-1 antitrypsin deficiency and Tay-Sachs disease.